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Abstract The approach to the pediatric patient with
membranous nephropathy (MN) can be challenging to the
practitioner. The clinical presentation of the child with this
histologic entity usually involves some degree of proteinuria
ranging from persistent, subnephrotic-ranged proteinuria to
overt nephrotic syndrome. Patients often have accompanying
microscopic hematuria and may have azotemia or mild
hypertension. Children presenting with nephrotic syndrome
are often steroid resistant; as such, their biopsy for steroid-
resistant nephrotic syndrome results in the diagnosis of MN.
The practitioner treating MN in the pediatric patient must
weigh the risks of immunosuppressive therapy against the
benefits. In general, the child with subnephrotic proteinuria
and normal renal function can likely be treated conservatively
with angiotensin blockade (angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers) without the need
for immunosuppressive therapy. Those with nephrotic syn-
drome are usually treated with steroids initially and often
followed by alkylating agents (cyclophosphamide or chlor-
ambucil). Calcineurin inhibitors may also be useful, but the
relapse rate after their discontinuation remains high. The
absence of controlled studies in children with MN makes
treatment recommendations difficult, but until they are
available, using the patient’s clinical presentation and risk of
disease progression appears to be the most prudent approach.
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Introduction
Membranous nephropathy (MN) is a rare histologic entity
in children, which usually presents as nephrotic syndrome
or asymptomatic proteinuria [1, 2]. Whereas it is one of the
most common causes of primary nephrotic syndrome in
adults, it contributes to <5% of cases in children [2–5]. It is
characterized histologically by the uniform thickening of
the glomerular capillary wall on light microscopy (Figs. 1
and 2). This thickening is associated with subepithelial
immune complex deposits that appear as granular deposits
of immunoglobulin (Ig) G on immunofluorescence and as
electron-dense deposits on electron microscopy. In children,
secondarycausesofMNhavebeenassociatedwithconditions
such as systemic lupus erythematosus (SLE), hepatitis B or C
infection, secondary and congenital syphilis, malaria, and
Ebstein Barr Virus (EBV) infection [1, 6, 7]. Other rare
underlying causes are C4 deficiency, selective IgA deficiency,
or antitubular basement membrane antibodies [8–10].
Epidemiology
Data from the International Study for Kidney Disease in
Children (ISKDC) demonstrated an incidence of MN in
1.5% in children with nephrotic syndrome [5]. Another
report by Moxey-Mims et al. showed that whereas the
incidence of MN was 1% in children 1–12 years of age, it
increased to 22% in children between the ages of 13 and
19 years [11]. Other studies have reported incidence of
idiopathic MN in children of 1.2−4.5% [4, 6, 12]. The
median age at presentation has ranged from 7 to 12 years in
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DOI 10.1007/s00467-009-1324-5various studies [2, 6, 12–14]. There is no specific gender
distribution, with the boy:girl ratio ranging from 3:1 to 1:1
[6, 13]. The 2008 report of the North American Pediatric
Renal Trials and Collaborative Studies (NAPRTCS) reports
the incidence of MN in children with chronic kidney
disease (CKD) to be 0.5% [15]. According to the United
States Renal Data System (USRDS) 2008 Annual Data
Report, MN contributes to 0.6% of cases of pediatric end-
stage renal disease (ESRD), with a median age at onset of
ESRD being 16 years [16].
Clinical features
Children with MN most commonly present clinically with
proteinuria, which may be nonselective and associated with
microscopic hematuria. Approximately 40−75% of patients
with MN present with nephrotic syndrome [2, 4]. Asymp-
tomatic, nephrotic-range proteinuria has been reported in
16−38% [2, 4]. Proteinuria may be associated with
microscopic hematuria in a majority of the patients [12].
Lee et al. reported an incidence of macroscopic hematuria
of almost 40% in their series of 19 children with idiopathic
MN from South Korea [13]. Hypertension may also be seen
in a small subset of patients at presentation.
Histology
The characteristic feature of MN on light microscopy is a
thickened glomerular capillary wall showing spikes on
silver and periodic acid-Schiff stains with granular staining
for IgG and complement component 3 along the capillary
wall on immunofluorescence [17]. The hallmark is the
presence of multiple, finely granular, electron-dense deposits
exclusively along the subepithelial surface of the glomerular
capillary wall between podocyte foot processes. Based on the
location of the deposits on electron microscopy, Ehrenreich
and Churg proposed a four-stage classification for MN [17,
18]. Stage 1 is characterized by small, sparsely distributed
electron-dense deposits on the epithelial side without
thickening of the glomerular basement membrane (GBM).
In stage 2, there are more extensive and larger subepithelial
deposits, with formation of basement membrane spikes
between the deposits and thickening of the GBM. Stage 3
lesions show a combination of stage 2 along with larger
deposits completely surrounded by basement membrane
(intramembranous deposits); and in stage 4, there is
incorporation ofdepositsinthe GBM and irregular thickening
and dissolution of the GBM.
Secondary causes
The overall prevalence of secondary causes of MN from
various adult series is believed to be close to 20% of all
patients with MN [10]. However, secondary causes appear
to be more common in children. Kleinknecht et al. reported
a prevalence of secondary causes in 30 of 85 children with
MN [6]. In another study from Korea, almost 75% cases of
MN were associated with a secondary cause [13]. This was,
however, very likely related to the high prevalence of
hepatitis B infection and hepatitis-B-related MN in this
region. The other conditions associated with MN include
hepatitis C, secondary and congenital syphilis, malaria,
SLE, sickle-cell hemoglobinopathy, and medications such
as D-penicillamine and gold salts [6, 7, 10]. Secondary MN
has also been seen following a hematopoietic cell transplant
Fig. 2 Primary membranous nephropathy (MN) (periodic acid-
methenamine silver-Jones stain; x400). Characteristic spike-like
epimembranous projections of basement membrane material on
capillary walls (arrows)
Fig. 1 Primarymembranousnephropathy(MN)(hematoxylinandeosin;
x200). Glomerular capillary walls are uniform with mild thickening
(arrows)
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tation [7]( T a b l e1).
It is important to differentiate between primary and
secondary MN due to differences in management and
outcome. Whereas there may be some clinical clues that
point toward a possible etiology, histology may also show
features suggestive of a secondary cause, especially that of
an autoimmune disease. Histologic features in favor of MN
associated with SLE include mesangial or endocapillary
proliferation on light microscopy, a “full-house” pattern of
Ig staining, including C1q and non-IgG4 on immunofluores-
cence microscopy, and tubuloreticular inclusions within the
glomerular endothelial cells on electron microscopy (Fig. 3).
Another potentially distinguishing histologic feature
includes the anatomic location of the electron-dense deposits.
In primary MN, these deposits are found exclusively in the
subepithelial and intramembranous region. In contrast, some
secondaryforms ofMN(thoserelatedtodrugssuchasgoldor
penicillamine) are characterized by deposits in the subendo-
thelial region of the capillary wall with a lower likelihood of
deposits in the subepithelial region. Membranous lupus
nephritis, however, cannot be distinguished from idiopathic
MN by the presence of subepithelial deposits, as they are
frequent in both types. On the other hand, mesangial deposits
have been reported to occur more commonly in membranous
lupus nephritis (Fig. 4)[ 19].
Pathogenesis
Due to the characteristic subepithelial immune complex
deposits seen on the electron microscopy, MN is believed to
be an immune-complex-mediated disease. However, no
circulating immune complexes have been identified in
patients with idiopathic MN. Most data on the pathogenesis
of MN comes from an animal model, the Heymann model
of experimental MN in rats, which suggests that the
podocyte is the target of injury. Studies show that there is
in situ binding of a circulating antibody to antigen in the
subepithelial space [7]. In the Heymann nephritis model,
megalin was identified as the antigenic target. However,
megalin, which is a member of the low-density lipoprotein
receptor family and is expressed with clathrin at the base of
podocyte foot processes (the site of immune complex
General causes Specific causes
Infections Hepatitis B
Hepatitis C
Streptococcal
Malaria
Schistosomiasis
Syphilis
Leprosy
Tuberculosis
Cytomegalovirus
Drugs Captopril
Clopidogrel
Mercury
Penicillamine
Nonsteroidal anti-inflammatory
Gold
Autoimmune diseases Systemic lupus erythematosus
Rheumatoid arthritis
Autoimmune thyroiditis
Sjögren’s syndrome
Mixed connective tissue disease
Neoplasms Carcinomas of bladder, breast, pancreas, prostate
Hematological malignancies: lymphoma, chronic lymphocytic leukemia
Others Diabetes mellitus
Sarcoidosis
Sickle-cell disease
Hematopoietic stem-cell transplant
Postrenal transplant
Table 1 Secondary causes of
membranous nephropathy
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[7, 20, 21]. Certain other podocyte membrane proteins,
such as dipeptidyl peptidase IV and neutral endopeptidase,
have been postulated to play an antigenic role in the
pathogenesis of MN [21, 22]. The identification on neutral
endopeptidase, as the target antigen in cases with neonatal
MN strongly supports the in situ immune complex
formation hypothesis [23].
The subepithelial immune complexes associated with MN
have been identified as consisting of IgG (usually IgG4) and
unidentified antigens [21]. T cells play a significant role in
the pathogenesis. The presence of IgG4, which is a product
of the type 2 response T helper cells (Th2) and an
upregulation of cytokines, such as interleukins (IL) -4 and
-10, suggest Th2 involvement [24, 25]. This CD4, T-cell-
dependent, humoral response leads to subsequent Ig deposi-
tion and complement activation. These observations are
further supported by experimental studies that show myco-
phenolate mofetil (MMF) prevents induction of Heymann
nephritis bycausingpreferential suppression of Th2 cytokines;
furthermore, this model of nephritis is modified by treatment
with monoclonal anti-CD4 and anti-CD8 treatment [26].
The formation of subepithelial immune deposits leads to
complement activation and subsequent insertion of sublytic
quantities of C5b-9 complex into the podocyte membrane
[7, 20, 21]. Various studies have shown that complement
activation and formation of C5b-9 is an important mediator
of podocyte injury in experimental MN. Inhibition of
complement deposition has been associated with the absence
ofproteinuriainthepassiveHeymannnephritismodelofMN,
despite not having any effect on antipodocyte antibody
deposits [25].
Complement activation triggers an inflammatory cascade
that includes upregulation of gene expression for production
of prostanoids, proteases, reactive oxygen species, extracellu-
lar matrix, and cytokines. Reactive oxygen species initiate
lipid peroxidation and degradation of GBM type IV collagen.
There is increased production of laminin and type IVand type
I collagen, whichaccumulatesinthe extracellular matrix.This
matrix accumulation gives MN its characteristic morpholog-
ical appearance with thickened basement membranes and
spike-like extensions of matrix between podocytes. C5b-9
also leads to abnormal distribution of slit diaphragm protein
with dissociation of nephrin from the actin cytoskeleton and
causes detachment of podocytes that are then shed into
Bowman’s space. Complement activation and C5b-9 decrease
nephrin expression and reduce F-actin-bound nephrin, thus
further interrupting slit diaphragm integrity [25]. Along with
the disruption of GBM, there is also podocyte apoptosis
mediated by reactive oxygen species [21]. The detachment of
podocytes from the GBM, as a result of both apoptosis and
cytoskeletal damage from C5b-9, contributes to an increase
in permeability of the protein filtration barrier. This sequence
of events disrupts the GBM and the protein filtration barrier
formed by podocytes, thereby resulting in proteinuria. Thus,
whereas the exact pathophysiologic mechanism is still
unclear, there is sufficient evidence to suggest the role of an
antigenictargetinthepodocytemembrane,withsubsequentin
situ subepithelial immune complex deposit formation and
accompanyingcomplementactivation,resultinginglomerular
injury and proteinuria.
Natural history
Due to the relatively low incidence of MN in children, most
data on its natural history and progression have been
Fig. 3 Secondary membranous nephropathy (MN) (lupus nephritis)
(electron microscopy x10,000). Tubuloreticular inclusion in cytoplasm
of endothelial cells (arrow)
Fig. 4 Secondary membranous nephropathy (MN) (lupus nephritis)
(electron microscopy x5,000). Subepithelial deposits are juxtaposed
with intervening glomerular basement membrane (thin arrows).
Mesangial deposits characteristic of lupus nephritis (thick arrows)
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often characterized by spontaneous remission and relapses.
In general, adults with MN are believed to be equally
divided into patients who show spontaneous remission,
those who have persistent proteinuria with preserved renal
function, and those who progress to ESRD [17, 20]. A
pooled analysis of randomized and prospective studies in
adults with MN showed a 10-year renal survival rate of
65−75% [27]. However, an important difference in the
clinical course between children and adults is that the
younger patients have been noted to have a relatively better
outcome. The older series by Olbing and others reported
rates of proteinuria remission of approximately 30% [6, 12].
Some of the more recent studies have reported higher overall
remission rates of 75% [2, 13]. The percentage of patients
with MN showing impaired renal function is also lower in
children.Accordingtothe2008AnnualReportofNAPRTCS,
MN contributes to 0.4 % of children on dialysis and 0.5 % of
children with CKD [15]. Lee et al. reported a 17.6% rate of
progression to chronic renal insufficiency [13]. In another
study, by Chen et al., one fourth of patients were in CKD
stage 3 (mean estimated GFR of 37±9 ml/min/1.73 m
2)a t
the end of a mean follow-up of 42 months [4]. In a series on
12 patients reported from our center, only one patient had an
eGFR<75 ml/min per 1.73 m
2 at a mean follow-up of
27 months [2].
Predictive factors
A number of adult studies have allowed practitioners to
characterize prognostic factors in adult patients with MN.
Laluck et al. showed that low-grade, subnephrotic proteinuria
and female gender were associated with spontaneous remis-
sion[28]. In a review on 350 patients with MN and nephrotic
syndrome, Troyanov et al. reported that the 10-year renal
survival rate was 100% in the complete remission group,
90% in the partial remission group, and 45% in the no
remission group [29]. Male gender, age >50 years, persistent
high-grade proteinuria, impaired renal function at onset,
presence of segmental glomerular sclerosis, and tubulointer-
stitial damage on the kidney biopsy have been considered to
be poor prognostic factors in adult idiopathic MN [7, 20].
The Toronto Glomerulonephritis Registry created a model
for identifying patients at risk for progression of renal
insufficiency, taking into account the initial creatinine
clearance (CrCl), the slope of the CrCl, and the lowest
amount of proteinuria during a 6-month period [30].
According to this model, patients who present with a normal
CrCl, proteinuria <4 g/24 h, and stable renal function over
6 months are considered to be at low risk for progression. On
the other hand, patients with persistent proteinuria (>8 g/24 h)
have a 66−80% probability of progression to ESRD within
10 years, independent of the degree of renal dysfunction. This
modelorananalogousmodelhasnotbeenappliedinchildren.
Various pediatric studies have tried to characterize the
prognostic factors in children with idiopathic MN. In their
series of nine patients, Olbing et al. noted that age <9 years
and normal blood pressure at the time of onset were
associated with a good prognosis [12]. They did not
observe any correlation between initial edema, proteinuria,
hypoalbuminemia, and hypercholesterolemia and the sub-
sequent course of disease. Other pediatric studies failed to
demonstrate any advantage of younger age and normal
blood pressure at presentation on final outcome.
There is some evidence from adult series that suggests that
histopathological staging of MN may be useful in predicting
prognosis and response to therapy [31]. In children, however,
there is no consistent data on the use of this histopathological
staging to predict response. Whereas Ramirez et al. reported
an increased rate of progression to renal insufficiency with
stage 3 and 4 lesions on initial biopsy compared with stage 1
or 2 lesions, this observation was not noted in a study of
CanadianchildrenwithMN[32, 33]. A few studies have noted
a correlation between chronic fe a t u r e ss u c ha sg l o m e r u l a r
sclerosis or tubulointerstitial changes on biopsy and disease
severity at onset or its response to treatment [20, 34].
Management
The treatment algorithm for managing MN in adults relies
on assessing the prognostic factors at illness onset and
trying to achieve a balance between the probability of renal
failure versus the risks of immunosuppression [17, 20].
According to the risk of renal disease progression, patients
are assigned to receive either conservative, nonimmuno-
suppressive therapy versus immunosuppressive therapy.
However, due to the rarity of the disease in the pediatric
population and the paucity of natural history studies, there
is no standardized approach to therapy in children. Most
knowledge in the pediatric literature pertaining to natural
history of MN, treatment options, and long-term outcome is
derived from small, uncontrolled case series (Table 2)[ 2, 4,
6, 13, 32]. None of the studies have shown consistency in
their therapeutic approaches, with differences in dosage and
duration of corticosteroids as well as use of other immuno-
suppressive and nonimmunosuppressive agents [angiotensin-
converting enzyme inhibitors (ACEi) or angiotensin receptor
blockers (ARB)].
There is evidence that not all children with MN merit
aggressive immunosuppressive treatment. Similar to adults, it
hasbeennotedthatchildrenwithasymptomatic,nonnephrotic
proteinuria have a better prognosis than those with nephrotic
syndrome. Hence, the primary aim of management is to avoid
aggressivetherapeuticmeasuresforpatientswhoarenotlikely
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divided into two groups based on their clinical presentation:
1. Children with asymptomatic, nonnephrotic proteinuria.
These children typically present with no edema, normal
serum albumin, and a urine protein to creatinine ratio
between 0.2 and 2 [35]. As it has been shown that this
group is at low risk of progressive renal disease, this
group of patients should be managed conservatively
with ACEi or ARB, with the goals of treatment being
to reduce proteinuria and optimize blood pressure
control. Whereas the effect of angiotensin blockade
has not been evaluated with controlled trials in
children, there is some inferential evidence from adults
on the benefits of ACEi or ARB. Gansevoort et al.
reported a 30% decrease in proteinuria in patients with
MN, especially in those who had lower levels of
proteinuria [36]. In another review of 348 patients,
Troyanov et al. reported a modest renoprotective effect
with the use of ACEi or ARB (hazard ratio for renal
survival on univariate analysis 0.40, p=0.009); however,
this advantage was not seen on multivariate analysis
[29]. There may be a potential synergistic antiproteinuric
effect of lipid-lowering agents when used with angioten-
sin blockade [17, 37]. Irrespective of the antiproteinuric
effect, lipid-lowering agents, particularly statins, play an
important role in the management of lipid abnormalities
with the aim of decreasing this cardiovascular risk factor.
2. Children with nephrotic syndrome. The standard
therapy for adults with MN and nephrotic proteinuria,
as defined as a urine protein to creatinine ratio >2, is
usually a combination of oral corticosteroids and
alkylating agents (chlorambucil or cyclophosphamide)
or cyclosporine [35]. The effects of these immunosup-
pressive agents have not yet been proven in children. A
few uncontrolled studies have reported the lack of
effectiveness of exclusively using oral corticosteroids
in children with MN [38]. On the other hand, there
have been some reports about the efficacy of combined
immunosuppressive therapy. Children with nephrotic
syndrome also benefit from concomitant treatment with
ACEi or ARB, and lipid-lowering agents for optimal
management of blood pressure and lipid abnormalities
(Fig. 5).
Medications (adults and children)
Corticosteroids A small number of prospective controlled
trials with corticosteroids have been reported in adults with
MN. These studies used different steroid regimens ranging
from low dose (45 mg/m
2 on alternate days for 6 months)
to high dose (100–150 mg on alternate days for 8 weeks).
The US Collaborative Study of Adult Idiopathic Nephrotic
Syndrome reported a significant reduction in the rate of
progression to renal failure [39]. However, a double-blind
study by the British Medical Research Council, which used
the same steroid dose in a larger patient population and
with a longer duration of follow-up, did not show any
beneficial effect of corticosteroids on renal function or
urinary protein excretion [40]. Cattran et al. and the Toronto
Study Group conducted a prospective randomized study in
which patients with idiopathic MN were assigned to receive
either alternate-day steroids for 6 months or no specific
treatment [41]. After a mean follow-up of 48 months, they
reported that there was no difference in the proportion of
patients achieving complete remission or those progressing
to renal failure.
Table 2 Pediatric membranous nephropathy studies
Author Number of
patients
NS Steroids Other immunosuppression Remission Persistent
disease
CRI ESRD
Habib et al. [55] 50 72% 54% 44% (mechlorethamine
and chlorambucil)
52% 38% ? 10%
Olbing et al. [12] 9 78% 89% 22% CYP, 11% AZA 33% 33% 33% 0%
Chan and Tsao [14] 10 80% 100% None 50% 40% 0% 10%
Trainin et al. [56] 14 79% 79% 57% “cytotoxics” 43% 29% 7% 21%
Latham et al. [33] 14 100% ≤ 93% ≤93%: CYP 29% 50% 7% 14%
Ramirez et al. [32] 22 82% 50% 5% AZA+CYP, 5% chlorambucil 27% 45% 23% 5%
Tsukahara et al. [57] 12 25% 42% 17% CYP 67% 33% 0% 0%
Lee et al. [13] 19 58% 84% 16% CsA 68% 16% 5% 11%
Chen et al. [4] 13 38% 77% 38% CNI, 23% AZA or MMF ? 61% 23% 0%
Valentini et al. [2] 12 75% 83% 58% CYP 75% 17% 8% 0%
CYP cyclophosphamide, AZA azathioprine, CsA cyclosporine, CNI calcineurin inhibitors, MMF mycophenolate mofetil, CRI chronic renal
insufficiency, ESRD end-stage renal disease
1424 Pediatr Nephrol (2010) 25:1419–1428To summarize, these controlled adult trials do not show a
definite advantage of using corticosteroids over placebo.
This was also confirmed by the Cochrane Review on
immunosuppressive treatment for idiopathic MN in adults
with nephrotic syndrome, which reported no beneficial
effect on total mortality or ESRD in patients treated with
glucocorticoids [relative risk (RR) 0.88, 95% confidence
interval (CI) 0.39−1.97, p=0.75] [42]. A similar analysis
has not been done in pediatrics.
Alkylating agents (cyclophosphamide or chlorambucil)
Alkylating agents such as cyclophosphamide and chlor-
ambucil emerged as a second-line therapy for MN as a
result of the uncertain efficacy of corticosteroids alone.
Ponticelli et al. noted that a 6-month course of intravenous
methylprednisolone and oral steroids alternating monthly
with chlorambucil was superior to conservative treatment in
inducing remission. Complete remission was achieved in
50% of cases compared with 7% of controls [43]. At
10 years, only 8% of treated cases had reached ESRD
compared with 40% of controls. Another randomized
controlled trial comparing a cyclic combination of steroids
and chlorambucil with cyclic steroids and oral cyclophos-
phamide observed that both treatment regimens were
equally effective in achieving remission and preserving
renal function [44]. However, cyclophosphamide was
associated with fewer side effects. According to the
Cochrane Review, alkylating agents showed a significant
effect on complete remission when compared with placebo
(RR 2.37, 95% CI 1.32−4.25, p=0.004) or with cortico-
steroids (RR 1.89, 95% CI 1.34−2.67, p=0.0003) [42].
Another meta-analysis of controlled trials of treatment with
cyclophosphamide or chlorambucil in patients with idio-
pathic MN and nephrotic-range proteinuria showed better
chances of achieving complete remission with cytotoxic
agents (RR 4.6, 95% CI 2.2 to 9.3) [45]. Our center reported
favorable outcomes with a 12-week course of oral cyclo-
phosphamide (2 mg/kg per day) in children with idiopathic
MN [2]. Six of seven patients (five steroid resistant, one each
partial responder and steroid dependent) achieved complete
remission with no significant adverse effects.
Calcineurin inhibitors
Cattran et al. conducted a randomized trial in patients with
idiopathic MN with nephrotic-range proteinuria comparing
26 weeks of cyclosporine (CsA) and low-dose prednisone
to placebo and prednisone [46]. They noted complete or
partial remission in 75% patients from the treatment group
versus 22% from the control group (p<0.001). Although
the rate of relapse after stopping CsA was high, at the end
Idiopathic Membranous Nephropathy in Children 
Steroid sensitive 
Asymptomatic non-
nephrotic proteinuria 
Nephrotic syndrome/ 
nephrotic range proteinuria 
ACE inhibitors/ Angiotensin 
receptor blockers 
? Lipid lowering agents 
Prednisone (4-8 weeks ) 
Alternate day steroids: 
Taper over 3-6 months
Steroid resistant 
Cyclophosphamide 
2mg/kg/day for 12 weeks 
Alternate day steroids 
Refractory disease: 
Consider calcineurin 
inhibitors 
(cyclosporine/tacrolimus) 
Fig. 5 Management of children
with idiopathic membranous
nephropathy
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remission in the CsA group compared with 13% in the
placebo group. Other studies have shown that CsA can
induce partial or complete remission in 50−60% of patients
[17]. Due to a high relapse rate after stopping cyclosporine,
prolonged low-dose CsA (approximately 1.5 mg/kg per
day) could be considered for patients who relapsed after
discontinuing CsA [17]. Due to undesirable cosmetic side
effects of CsA, namely, hirsutism and gingival hyperplasia,
tacrolimus is emerging as a useful alternative. In a
prospective randomized trial, Praga et al. evaluated mono-
therapy with tacrolimus in adult patients with MN [47].
Twenty-fivepatientsweretreatedwithtacrolimus(0.05mg/kg
per day) over 12 months with a 6-month taper and compared
with 23 controls. At the end of 18 months, the probability of
remission in the treatment group was 94% versus 35% in the
control group. There was relapse of nephrotic syndrome in
almost half of the patients after tacrolimus withdrawal.
Despite these adult studies on CsA and tacrolimus, there is
very limited published literature on the use of calcineurin
inhibitors in pediatric MN [4, 13].
Mycophenolate mofetil (MMF)
MMF has been used in uncontrolled trials in adults with
idiopathic MN. Miller et al. reported a 50% reduction in
proteinuria in 6/16 patients who received treatment with
MMF for a mean period of 8 months [48]. Another
retrospective study in 17 patients reported a decrease in
the median urine protein:creatinine ratio from 7.3 to 1.5
(p=0.001) [7]. There are no published pediatric reports of
MMF use in children with MN.
Rituximab
DuetothepossibleroleofB-cellactivationinthepathogenesis
of MN, targeted B-cell therapy is being tried to stop the
production of pathogenic antibodies and prevent further
glomerular damage. In a pilot study of rituximab (four weekly
infusions of 375 mg/m
2) in eight patients with idiopathic MN
with persistent nephrotic syndrome, Remuzzi et al. noted a
70% decline in albuminuria at week 20 [49]. In another
prospective, open-label trial, 60% of patients achieved
complete or partial remission, and there was a 48% reduction
in proteinuria [17]. Bomback et al. recently conducted a
systematic review on the use of rituximab for MN. They
noted that in primary MN, rituximab achieved complete
remission in 13–20% of patients, and partial remission was
seen in 36–50%. Fourteen of the 17 studies in their review,
which reported their rituximab protocols, used rituximab at
375 mg/m
2 once weekly for 4 weeks. They noted that more
prospective studies and randomized controlled trials were
needed before rituximab could be considered an alternative
to alkylating agents and calcineurin inhibitors [50]. Whereas
the early adult outcomes are compelling, unknown long-term
side effects of rituximab makes its use in the pediatric patient
withMNlikelyrestrictedtochildrenwithnephrotic syndrome
refractory to traditional immunosuppressive medication.
Posttransplantation membranous glomerulopathy
Idiopathic MN recurs in 10–30% of patients after kidney
transplantation [51]. De novo MN, which is the most
common de novo glomerulopathy in renal allografts, affects
2–9% of renal allografts [52]. De novo MN typically occurs
24–36 months posttransplant and recurrent MN after 10–
24 months [53]. The exact pathogenesis of de novo MN is
not clear. Recently, El Kossi et al. described a case of de
novo MN in which the onset of nephrotic-range proteinuria
was associated with a donor-specific antibody directed
against a class II human leukocyte antigen (HLA) DQ7
[53]. The patient was treated successfully with MMF and
an ARB. Remission of proteinuria was associated with a
fall in the anti-DQ7 titer. The authors postulated that de
novo membranous glomerulopathy could be considered an
atypical manifestation of acute antibody-mediated damage.
There are limited dataon the treatment ofrecurrent ordenovo
MN. Some studies have reported the lack of any benefit from
the use of steroids and other immunosuppressive drugs [51,
54]. However, others have reported some success with the
standard drugs used for idiopathic MN [53].
Summary
MN in the pediatric patient poses many challenges to the
pediatric nephrologist due to its infrequent occurrence,
varying means of presentation, and inconsistent treatment
response. Pediatric studies discourage the use of immuno-
suppressive medication in asymptomatic patients with
minimal (subnephrotic) proteinuria. However, several un-
controlled case series support the use of corticosteroids
coupled with alkylating agents for pediatric patients with
MN and nephrotic syndrome. Fewer studies exist as to the
role of calcineurin inhibitors in this setting. Other agents such
as MMF and rituximab have not been studied in children to
date. The prognosis of a child with MN has to be considered
guarded, with the greatest attention being given to those with
refractory proteinuria and/or altered renal function.
Acknowledgments The authors thank Xu Zeng, Department of
Laboratory Medicine and Pathology, Wayne State University, Detroit,
MI, USA, for his assistance with the renal pathology slides.
1426 Pediatr Nephrol (2010) 25:1419–1428Questions
(Answers appear following the reference list)
1. Which of the following would be the LEAST expected
clinical presentation of a child diagnosed with idiopathic
MN?
a. Asymptomatic proteinuria
b. Azotemia
c. Hypertension
d. Microscopic hematuria
e. Nephrotic syndrome
2. All of the following would be an expected association
of secondary MN EXCEPT?
a. Celiac disease
b. Hepatitis B infection
c. Nonsteroidal anti-inflammatory drugs
d. Sarcoidosis
e. Systemic lupus erythematosus
3. A key histologic feature distinguishing MN associated
withsystemiclupuserythematosusfromthatofidiopathic
MN is
a. C3 staining on immunofluorescence
b. Granular staining for IgG
c. Subepithelial electron-dense deposits
d. Thickened glomerular capillary walls
e. Tubuloreticular inclusions
4 Which of the following treatment strategies best
characterizes the approach to a child with MN?
a. Alkylating agents with corticosteroids should be con-
sidered for children with MN and nephrotic syndrome
and steroid-resistant disease
b. ACEi should be reserved for patients with refractory,
nephrotic-range proteinuria
c. Calcineurin inhibitors appear to be effective in MN, with
a low relapse rate upon discontinuation of medication
d. Oral corticosteroids should be used in all patients
irrespective of clinical presentation
e. Rituximabappears tobea suitablesecond-line therapyfor
children with steroid-resistant MN based on published
reports
5. Which of the following factors are associated with a
favorable prognosis in the pediatric patient with MN?
a. Age <14 years
b. Azotemia
c. Male gender
d. Tubulointerstitial fibrosis
e. Subnephrotic proteinuria
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